

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJLK1617

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JAN 02 STN pricing information for 2008 now available  
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified  
prophetic substances  
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new  
custom IPC display formats  
NEWS 5 JAN 28 MARPAT searching enhanced  
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days  
of publication  
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment  
NEWS 8 JAN 28 MEDLINE and LMEEDLINE reloaded with enhancements  
NEWS 9 FEB 08 STN Express, Version 8.3, now available  
NEWS 10 FEB 20 PCI now available as a replacement to DPCI  
NEWS 11 FEB 25 IFIREF reloaded with enhancements  
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements  
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current  
U.S. National Patent Classification  
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom  
IPC display formats  
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental  
spectra  
NEWS 16 MAR 31 CA/CAPLUS and CASREACT patent number format for U.S.  
applications updated  
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI  
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued  
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new  
predefined hit display formats  
  
NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 12:10:14 ON 17 APR 2008

=> FILE REG		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:10:26 ON 17 APR 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 APR 2008 HIGHEST RN 1015083-77-8  
DICTIONARY FILE UPDATES: 15 APR 2008 HIGHEST RN 1015083-77-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> E hydrowuinone/CN

E1	1	HYDROWOODWARDITE/CN
E2	1	HYDROWOODWARDITE (((CU0.5-1ZN0-0.5)2.67-6AL2-5.33)(OH)16(SO4) 1-2.67.XH2O)/CN
E3	0 -->	HYDROWUINONE/CN
E4	1	HYDROX/CN
E5	1	HYDROXAL/CN
E6	1	HYDROXAL 8154/CN
E7	1	HYDROXAL PMH-IV/CN
E8	1	HYDROXAMATE GLUCOSYLTRANSFERASE/CN
E9	1	HYDROXAMATE METHYLTRANSFERASE/CN
E10	1	HYDROXAMATE-DEPENDENT IRON UPTAKE, CYTOPLASMIC MEMBRANE COMP ONENT (ESCHERICHIA COLI O157:H7 STRAIN EDL933 GENE FHUB)/CN
E11	1	HYDROXAMATE-DEPENDENT IRON UPTAKE, CYTOPLASMIC MEMBRANE COMP ONENT (ESCHERICHIA COLI O157:H7 STRAIN EDL933 GENE FHUB)/CN
E12	1	HYDROXAMATE-DEPENDENT IRON UPTAKE, CYTOPLASMIC MEMBRANE COMP ONENT (SHIGELLA BOYDII STRAIN SB227 GENE FHUB)/CN

=> E hydroquinone/CN

E1	1	HYDROQUINOLBIS(DI(2,6-DIMETHYLPHENYL)) PHOSPHATE/CN
E2	1	HYDROQUINON-8-HYDROXYQUINOLINE COPOLYMER/CN
E3	1 -->	HYDROQUINONE/CN
E4	1	HYDROQUINONE (2-NITRO-P-TOLYL)-, DIACETATE/CN
E5	1	HYDROQUINONE B-D-GLUCOPYRANOSIDE/CN
E6	1	HYDROQUINONE 2,6-DIMETHYLHEPTYL ETHER/CN
E7	1	HYDROQUINONE 85KR-KRYPTONATE (3:1)/CN
E8	1	HYDROQUINONE 9-PHENANTHRYL ETHER/CN
E9	1	HYDROQUINONE ALLYL GLYCIDYL ETHER/CN
E10	1	HYDROQUINONE ALLYL GLYCIDYL ETHER-N-VINYLPYRROLIDINONE COPOL

YMER/CN  
 E11 1 HYDROQUINONE ALUMINUM SALT/CN  
 E12 1 HYDROQUINONE AMMONIUM SULFONATE/CN

=> S E3

L1 1 HYDROQUINONE/CN

=> E stearyltrimethylammonium chloride/CN

E1 1 STEARYLTRIMETHYLAMMONIUM/CN  
 E2 1 STEARYLTRIMETHYLAMMONIUM BROMIDE/CN  
 E3 1 --> STEARYLTRIMETHYLAMMONIUM CHLORIDE/CN  
 E4 1 STEARYLTRIMETHYLAMMONIUM ETHYL SULFATE/CN  
 E5 1 STEARYLTRIMETHYLAMMONIUM IODIDE/CN  
 E6 1 STEARYLTRIMETHYLAMMONIUM METHYL SULFATE/CN  
 E7 1 STEARYLTRIMETHYLAMMONIUM PENTACHLOROPHENATE/CN  
 E8 1 STEARYLTRIMETHYLAMMONIUM PERCHLORATE/CN  
 E9 1 STEARYLTRIMETHYLPHOSPHONIUM BROMIDE/CN  
 E10 1 STEARYLTRIMETHYLPHOSPHONIUM CHLORIDE/CN  
 E11 1 STEARYLTRIMONIUM BROMIDE/CN  
 E12 1 STEARYLTRIMONIUM CHLORIDE/CN

=> S E3

L2 1 "STEARYLTRIMETHYLAMMONIUM CHLORIDE"/CN

=> FILE CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.22	11.43

FILE 'CAPLUS' ENTERED AT 12:11:29 ON 17 APR 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Apr 2008 VOL 148 ISS 16  
 FILE LAST UPDATED: 16 Apr 2008 (20080416/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L1 and L2

22869 L1

2774 L2

L3 10 L1 AND L2

=> D 1-10 IBIB ABS

L3 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2006:1224983 CAPLUS

DOCUMENT NUMBER: 145:510940  
 TITLE: Regulation of mammalian keratinous tissue using personal care compositions comprising cetyl pyridinium chloride  
 INVENTOR(S): Bissett, Donald Lynn  
 PATENT ASSIGNEE(S): The Procter & Gamble Company, USA  
 SOURCE: PCT Int. Appl., 40pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006124990	A2	20061123	WO 2006-US19067	20060517
WO 2006124990	A3	20070322		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20070020221	A1	20070125	US 2006-391812	20060329
EP 1885326	A2	20080213	EP 2006-770489	20060517
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:				
			US 2005-681626P	P 20050517
			US 2005-722384P	P 20050930
			US 2006-391812	A 20060329
			WO 2006-US19067	W 20060517

AB This invention relates to personal care composition including a first skin and/or hair care active cetyl pyridinium chloride; and at least one addnl. skin and/or hair care active selected from the group consisting of tetrahydrocurcumin, sugar amine, vitamin B3, retinoids, hydroquinone, peptides, phytosterol, dialkanoyl hydroxyproline, hexamidine, salicylic acid, n-acyl amino acid compds., sunscreen actives, water soluble vitamins, oil soluble vitamins, hesperidin, mustard seed extract, glycyrrhizic acid, glycyrrhetic acid, carnosine, Butylated Hydroxytoluene (BHT) and Butylated Hydroxyanisole (BHA), ergothioneine, vanillin or its derivs., diethylhexyl syringylidene malonate, melanostatin, sterol esters, idebenone, dehydroacetic acid, Licohalcone A, creatine, creatinine, feverfew extract, yeast extract, beta glucans, alpha glucans, their salts, their derivs., their precursors, and/or combinations thereof; and a dermatol. acceptable carrier. The invention further relates to methods for regulating the condition of mammalian keratinous tissue wherein the methods each comprise the step of topically applying to the keratinous tissue of a mammal needing such treatment, a safe and effective amount of the personal care composition of the invention.

L3 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2008 ACS ON STN  
 ACCESSION NUMBER: 2006:131012 CAPLUS  
 DOCUMENT NUMBER: 145:382901  
 TITLE: Development of new whitening agents with hydroquinone stabilized by the complex formation with surfactants

and the evaluation for melanogenesis inhibitory effect and skin stimulus

AUTHOR(S): Iimura, Nahoko; Maruyama, Tomohiro; Kitagawa, Shuji; Ohashi, Yuji

CORPORATE SOURCE: Department of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 5-13-2 Kamishin'ei-cho, Niigata, 950-2081, Japan

SOURCE: Nippon Koshohin Gakkaishi (2005), 29(4), 301-313  
CODEN: NKGIBW; ISSN: 1880-2532

PUBLISHER: Nippon Koshohin Gakkai

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB Hydroquinone is well known as dermatologists for skin de-pigmentation since it has a melanogenesis inhibitory effect and has been used clin. However, hydroquinone easily changes its structure on exposure to light or oxygen and upon heating. As a result, its color became brown or black. Recently we found that hydroquinone makes complexes with a variety of surfactant mols. When the complex was formed, hydroquinone was stabilized without coloration. X-ray crystal structure anal. of the complexes revealed that the hydroquinone mol. is closely packed and covered with the surfactant mols. in the crystalline lattice. Among the complexes, a complex between hydroquinone and benzyl (hexadecyl) dimethylammonium chloride was examined in detail to estimate its skin stimulus and safety. Moreover, the melanogenesis inhibitory effect was evaluated clin. In every examination, the complex showed a very good indication for the whitening agent.

L3 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:285009 CAPLUS

DOCUMENT NUMBER: 142:429768

TITLE: Crystal structures of two molecular complexes between cationic surfactants and hydroquinone showing a melanogenesis inhibitory effect

AUTHOR(S): Iimura, Nahoko; Fujimura, Yuko; Sekine, Akiko; Kitagawa, Shuji; Ohashi, Yuji

CORPORATE SOURCE: Department of Pharmaceutics, Niigata University of Pharmacy and Applied Life Sciences, Niigata, 950-2081, Japan

SOURCE: Bulletin of the Chemical Society of Japan (2005), 78(3), 418-423

CODEN: BCSJA8; ISSN: 0009-2673

PUBLISHER: Chemical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Hydroquinone, showing a melanogenesis inhibitory effect, formed crystalline mol. complexes with two cationic surfactants of benzyl(hexadecyl)dimethylammonium chloride and ethyl(hexadecyl)dimethylammonium bromide from a methanol solution at low temps., lower than 15 °C. The crystal structures were analyzed by X-rays at 223 K. There are two crystallog. independent hydroquinone mols. and one surfactant mol. in each crystal. One of the hydroquinone mols. is sandwiched by the surfactant mols. and makes a "common packing pattern," which has been observed in complex crystals between aromatic compds. and surfactant mols. Another hydroquinone occupies an inversion center surrounded by the benzyl(dimethylammonium or ethyl(dimethylammonium) moiety of the surfactant mol. Such a close packing makes hydroquinone in the mol. complex stable in open air at room temperature

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:182077 CAPLUS

DOCUMENT NUMBER: 142:284789

TITLE: Antiaging cosmetics containing antioxidants and free-radical neutralizing agents and antiinflammatories and collagen/fibrin boosting agents

INVENTOR(S): Gupta, Shyam K.

PATENT ASSIGNEE(S): Bioderm Research, USA

SOURCE: U.S. Pat. Appl. Publ., 9 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050048008	A1	20050303	US 2003-604999	20030829
US 7320797	B2	20080122		

PRIORITY APPLN. INFO.: US 2003-604999 20030829

AB The present invention provides a comprehensive solution to the problems associated with natural topical aging via the incorporation of an extra-cellular antioxidant or free-radical neutralizing composition, with intra-cellular antioxidant or free-radical neutralizing composition, and anti-inflammatory composition, and collagen or fibrin boosting composition. It is preferred to also have the above incorporated in a suitable carrier base or topical delivery system for skin, nail, and hair beneficial applications. For example, a shampoo composition contained sodium lauryl ether sulfate 35.0, water 55.4, cinnamidopropyl trimonium N-acetyl cysteinate 5.0, preservatives 0.5, Laureth-3 2.5, Rosmarinic acid 0.1, Darutoside 1.0, Niacinamide ascorbate 0.5%.

L3 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:569681 CAPLUS

DOCUMENT NUMBER: 141:117191

TITLE: Seborrheic keratosis treatment using hydrogen peroxide

INVENTOR(S): Ancira, Margaret; Miller, Mickey

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 72,829.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040137077	A1	20040715	US 2003-684136	20031009
US 20030008018	A1	20030109	US 2002-72829	20020208
US 7138146	B2	20061121		
AU 2007203283	A1	20070802	AU 2007-203283	20070716

PRIORITY APPLN. INFO.: US 2001-267978P P 20010209

US 2002-72829 A2 20020208

AU 2002-251894 A3 20020208

AB The subject of the present invention is seborrheic keratosis removal and prevention utilizing safe dependable effective biocompatible treatments with no scarring, bleeding, burning, freezing, shocking, and hypopigmentation or hyperpigmentation. Seborrheic keratoses are removed by: (a) obtaining a composition comprising hydrogen peroxide in a concentration of at least about 23 %; and (b) applying the composition to a seborrheic keratosis on a seborrheic keratoses afflicted person or domesticated animal. Patients were treated with applications of 35 % hydrogen peroxide. Compns. are

presented.

L3 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:252319 CAPLUS  
DOCUMENT NUMBER: 140:275765  
TITLE: Whitening agent containing crystalline molecular  
complex of hydroquinone with surfactant  
INVENTOR(S): Ohashi, Yuji; Iimura, Nahoko  
PATENT ASSIGNEE(S): The Circle for the Promotion of Science and  
Engineering, Japan  
SOURCE: PCT Int. Appl., 60 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024116	A1	20040325	WO 2003-JP11590	20030910
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
JP 2004099542	A	20040402	JP 2002-264636	20020910
JP 3712066	B2	20051102		
AU 2003262063	A1	20040430	AU 2003-262063	20030910
CN 1688283	A	20051026	CN 2003-823841	20030910
US 20060140888	A1	20060629	US 2005-527078	20051122
PRIORITY APPLN. INFO.:			JP 2002-264636	A 20020910
			WO 2003-JP11590	W 20030910

AB It is intended to provide (i) a hydroquinone-containing whitening agent showing a high storage stability and the sustained-release of hydroquinone, (ii) a process for producing the whitening agent, and (iii) a method of whitening the skin with the use of the whitening agent. The above-described whitening agent is characterized by containing a crystalline

mol. complex comprising hydroquinone or its derivative with a surfactant and, owing to the formation of the mol. complex, the storage stability to heat, oxygen or light of the hydroquinone-containing whitening agent as described above being improved and hydroquinone being released in a sustained state so that the whitening effect of the whitening agent can be sustained. Thus, a complex of hydroquinone and hexadecyldimethylbenzylammonium chloride showed good antioxidant and heat stability.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:637534 CAPLUS  
DOCUMENT NUMBER: 137:190733  
TITLE: Hydrogen peroxide-containing compositions for removal of acrochordon  
INVENTOR(S): Miller, Mickey; Ancira, Margaret  
PATENT ASSIGNEE(S): Physician's Choice of Arizona, Inc., USA  
SOURCE: PCT Int. Appl., 31 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064151	A1	20020822	WO 2002-US3530	20020208
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2437823	A1	20020822	CA 2002-2437823	20020208
AU 2002251894	A1	20020828	AU 2002-251894	20020208
EP 1365781	A1	20031203	EP 2002-720927	20020208
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
CN 1501804	A	20040602	CN 2002-807988	20020208
JP 2004518715	T	20040624	JP 2002-563944	20020208
BR 2002007163	A	20040629	BR 2002-7163	20020208
NZ 527673	A	20050324	NZ 2002-527673	20020208
MX 2003PA07151	A	20041015	MX 2003-PA7151	20030808
IN 2003DN01310	A	20050527	IN 2003-DN1310	20030818
AU 2007203283	A1	20070802	AU 2007-203283	20070716
PRIORITY APPLN. INFO.:			US 2001-267978P	P 20010209
			AU 2002-251894	A3 20020208
			WO 2002-US3530	W 20020208

AB The subject of the present invention is acrochordon removal and prevention utilizing safe dependable effective biocompatible treatments with no scarring, bleeding, twisting, yanking, choking, burning, freezing, shocking, screaming and hypo pigmentation or hyper pigmentation. Methods for acrochordon removal comprise application of high concns. of hydrogen peroxide (at least 23%). The composition further comprises a vitamin, an amino acid, a melanin inhibitor, an organic acid, a hormone, a sulfoxide, an alc., a fatty acid, a polyol, an amide, a surfactant, a terpene, etc. For example, the composition comprises 35% hydrogen peroxide, 0.5% L-ascorbic acid, 0.5% niacin, 0.5% glycine, 0.5% hydroquinone, 0.5% superoxide dismutase, 5% galacturonic acid, and 14% ethanol.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1997:722822 CAPLUS  
 DOCUMENT NUMBER: 128:16078  
 TITLE: Does the semi-continuous activated sludge (SCAS) test predict removal in secondary treatment?  
 AUTHOR(S): Boethling, Robert S.; Howard, Philip H.; Stiteler, William; Hueber, Amy  
 CORPORATE SOURCE: Office of Pollution Prevention and Toxics (7406), U.S. Environmental Protection Agency, Washington, DC, 20460, USA  
 SOURCE: Chemosphere (1997), 35(10), 2119-2130  
 CODEN: CSMHAF; ISSN: 0045-6535  
 PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The SCAS test was formalized by the US Soap and Detergent Association in 1965.



The SCAS procedure has also been adopted by the Organization for Economic Cooperation and Development as a test for inherent biodegradability and by the US EPA as a test guideline (40CFR 835.3120) under the Toxic Substances Control Act. To study whether the SCAS test may be used to predict removal in full-scale activated sludge treatment systems, we collected all available SCAS data for organic chems., and retrieved data from full-, pilot- or bench-scale continuous-feed activated sludge studies for the chems. that had SCAS data. The intersected file was subjected to statistical anal. Conclusions are: (1) SCAS data were strongly clustered at high (>90%) removal; (2) for SCAS removal >90%, it is probable that removal in the field will be >50%; (3) however, for SCAS removal <90% adequate treatability cannot be predicted with confidence.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:707977 CAPLUS  
DOCUMENT NUMBER: 121:307977  
TITLE: Hair dyes containing polymerization inhibitors  
INVENTOR(S): Sasai, Takashi; Mizushima, Yukako  
PATENT ASSIGNEE(S): Lion Corp, Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06199641	A	19940719	JP 1992-348930	19921228
PRIORITY APPLN. INFO.:			JP 1992-348930	19921228

AB The hair dyes contain oxidative polymerization products of oxidation dyes and/or nitro dyes and polymerization inhibitors. The hair dyes are stable and show good dyeing fastness without damaging hair. An aqueous solution of p-C<sub>6</sub>H<sub>4</sub>(NH<sub>2</sub>)<sub>2</sub> (I) was treated with an aqueous H<sub>2</sub>O<sub>2</sub> solution at 49-50° for 1 h to give a trimer of I (II). II 5, 2-hydroxy-1,4-naphthoquinone 0.5, stearyltrimethylammonium chloride 1.0, lauryldimethylamino acetic acid betaine 10, lanolin 1, and H<sub>2</sub>O 82.5 g were mixed to give a hair dye. Dyeing performance of the dye on storage at room temperature for 2 mo was excellent.

L3 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:89947 CAPLUS  
DOCUMENT NUMBER: 106:89947  
ORIGINAL REFERENCE NO.: 106:14667a,14670a  
TITLE: Topical compositions containing cationic surfactants and hydroquinone derivatives  
INVENTOR(S): Fujinuma, Yoshimori; Kita, Seiichi; Abe, Shintaro  
PATENT ASSIGNEE(S): Shiseido Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61225114	A	19861006	JP 1985-64207	19850328

JP 05079641  
PRIORITY APPLN. INFO.:  
GI

B 19931104

JP 1985-64207

19850328



AB Topical compns. contain at least one cationic surfactant and at least one hydroquinone derivative (I; R = pentose, hexose, amino sugar, uronic acid residue, etc.). The irritating effect of cationic surfactants of cosmetics is controlled by I. Thus, a hair rinse consisted of stearyltrimethylammonium chloride 3.0, cetanol 2.0, silicone oil 3.0, polyoxyethylene oleyl alc. ether 1.0, hydroquinone- $\beta$ -D-glucose 1.0, a perfume 0.1, ethylparaben 0.2, and H<sub>2</sub>O to 100% by weight

=> END

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
29.58	41.01

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-8.00	-8.00

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 12:12:06 ON 17 APR 2008